Positive Results In Study of Novartis Drug Afinitor (NVS)

Novartis AG (NYSE: NVS) reported after the close today, November 3rd The New England Journal of Medicine published a study which found patients taking Afinitor tablets saw a decrease in the size of their subependymal giant cell astrocytoma. Astrocytoma's are a benign brain tumor associated with TB 1 and 2.

The company stated during a presentation at the 46th annual American Society of Clinical Oncology annual meeting this is the first study to show a beneficial use of the drug in patients.

Day's Range: 57.90 - 58.62
52wk Range: 43.48 - 60.07